Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2021 | COR388: a novel approach to treating Alzheimer’s based on the gingipain hypothesis

Michael Detke, MD, PhD, Cortexyme, South San Francisco, CA, discusses the use of COR388 (atuzaginstat), a novel investigational virulence factor inhibitor targeting gingipains from Porphyromonas gingivalis (P. gingivalis), for the treatment of Alzheimer’s disease. COR388 was developed based on the gingipain hypothesis of Alzheimer’s which proposes that P. gingivalis infection of brain tissue acts in Alzheimer’s pathogenesis through the secretion of gingipains to promote neuronal damage. P. gingivalis resides in vacuoles within human cells and cannot be targeted with currently available antibiotics. By targeting gingipains, COR388 aims to prevent the damage caused to cells by these proteases, as well as starve off the food supply to the bacteria. This interview took place during the Alzheimer’s Association International Conference 2021.


Dr Detke is a full-time employee of Cortexyme and has CRTX stock options.